Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): Results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial

Critical Care

Volumn 22, Issue 1, 2018, Pages

  Curry, Nicola ^a,b   Foley, Claire ^c   Wong, Henna ^a,b,d   Mora, Ana ^c   Curnow, Elinor ^c   Zarankaite, Agne ^c   Hodge, Renate ^c   Hopkins, Valerie ^c   Deary, Alison ^c   Ray, James ^e   Moss, Phil ^f   Reed, Matthew J ^g   Kellett, Suzanne ^h   Davenport, Ross ⁱ   Stanworth, Simon ^a,b,d,e  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f ST GEORGE S HOSPITAL   (United Kingdom)

^g ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^h UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

ⁱ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cryoprecipitate; Fibrinogen replacement therapy; Haemorrhagic shock; Multiple trauma; Transfusion

Indexed keywords

FIBRINOGEN; FIBRINOGEN CONCENTRATE; PLACEBO; HEMOSTATIC AGENT;

ADULT; ALL CAUSE MORTALITY; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; MALE; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TIME TO TREATMENT; TREATMENT OUTCOME; UNITED KINGDOM; CLINICAL TRIAL; COMPLICATION; INJURY; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; STANDARDS;

ADULT; DOUBLE-BLIND METHOD; FEMALE; FIBRINOGEN; HEMORRHAGE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; PRAGMATIC CLINICAL TRIALS AS TOPIC; SECONDARY PREVENTION; TREATMENT OUTCOME; UNITED KINGDOM; WOUNDS AND INJURIES;

EID: 85048994292     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-018-2086-x     Document Type: Article

References (30)

1. Tisherman SA, Schmicker RH, Brasel KJ, Bulger EM, Kerby JD, et al. Detailed description of all deaths in both the shock and traumatic brain injury hypertonic saline trials of the resuscitation outcomes consortium. Ann Surg. 2015;261:586-90.
2. Davenport R, Guerreiro M, Frith D, Rourke C, Platton S, et al. Activated protein C drives the hyperfibrinolysis of acute traumatic coagulopathy. Anaesthesiology. 2017;126:115-27.
3. Raza I, Davenport R, Rourke C, Platton S, Manson J, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013;11:307-14.
4. Rourke C, Curry N, Khan S, Taylor R, Raza I, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost. 2012;10:1342-51.
5. McQuilten ZK, Wood EM, Bailey M, Cameron PA, Cooper DJ. Fibrinogen is an independent predictor of mortality in major trauma patients: a five-year statewide cohort study. Injury. 2017;48:1074-81.
6. Khan S, Brohi K, Chana M, Raza I, Stanworth S, et al. Hemostatic resuscitation is neither hemostatic nor resuscitative in trauma hemorrhage. J Trauma Acute Care Surg. 2014;76:561-7.
7. Wong H, Curry N. Do we need cryoprecipitate in the era of fibrinogen concentrate and other specific factor options? Vox Sang. 2017;13:23-8. https://doi.org/10.1111/voxs.12376.
8. Jensen NHL, Stensballe J, Afshari A. Comparing efficacy and safety of fibrinogen concentrate to cryoprecipitate in bleeding patients: a systematic review. Acta Anaesthesiol Scand. 2016;60:1033-42. https://doi.org/10.1111/aas.12734.
9. Curry N, Rourke C, Davenport R, Beer S, Pankhurst L, et al. Early cryoprecipitate for major haemorrhage in trauma: a randomised controlled feasibility trial. Br J Anaesth. 2015;115:76-83.
10. Nascimento B, Callum J, Tien H, Peng H, Rizoli S, et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. Br J Anaesth. 2016;117:775-82.
11. Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. Red book: guidelines for the blood transfusion services in the UK. 8th ed. https://www.transfusionguidelines.org/red-book. Accessed 14 Apr 2018.
12. Hagemo JS, Stanworth SJ, Juffermans NP, Brohi K, Cohen M, et al. Prevalence, predictors and outcome of hypofibrinogenaemia in trauma: a multicenter observational study. Crit Care. 2014;18:R52.
13. Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tønnesen E, et al. Fibrinogen substitution improves whole blood clot firmness in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost. 2009;7:795-802.
14. Bruynseels D, Solomon C, Hallam CPW, Collis RE, et al. Commentary on reconstituting fibrinogen concentrate to maintain blinding in a double-blind, randomized trial in an emergency setting. J Emerg Med. 2016;50:104-7.
15. Collins PW, Cannings-John R, Bruynseels D, Mallaiah S, Dick J, et al. Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. Br J Anaesth. 2017;119:411-21.
16. Hunt BJ, Allard S, Keeling D, Norfolk D, Stanworth SJ, et al. British Committee for Standards in Haematology. A practical guideline for the haematological management of major haemorrhage. Br J Haematol. 2015;170:788-803.
17. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. 2007;369:836-43.
18. EQ-5D-5L user guide: basic information on how to use the EQ-5D-5L instrument. Version 2.1. April 2015. https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf. Accessed 18 Oct 2017.
19. Altman DG, Schulz KF, Moher D, CONSORT Group. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663-94.
20. Karri JV, Cardenas JC, Johansson PI, Matijevic N, Cotton BA, Wade CE, Holcomb JB. In vitro efficacy of RiaSTAP after rapid reconstitution. J Surg Res. 2014;190:655-61. https://doi.org/10.1016/j.jss.2014.01.055.
21. Ponschab M, Voelckel W, Pavelka M, Schlimp CJ, Schochl H. Effect of coagulation factor concentrate administration on ROTEM® parameters in major trauma. Scand J Trauma Resusc Emerg Med. 2015;23:84.
22. Innerhofer P, Fries D, Mittermayr M, Innerhofer N, von Langen D, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-Centre, parallel-group, open-label, randomised trial. Lancet Haematol. 2017;4:e258-71.
23. Lochandwala PM, O'Neal A, Patel EU, Brunker PAR, Gehrie EA, et al. Hemostatic profile and safety of pooled cryoprecipitate up to 120 hours after thawing. Transfusion. 2018;58:1126-31.
24. Schöchl H, Nienaber U, Hofer G, Voelckel W, Jambor C, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010;14:R55.
25. Gonzalez E, Moore EE, Moore HB, Chapman MP, Chin TL, et al. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg. 2016;263:1051-9.
26. Stein P, Kaserer A, Sprengel K, Wanner GA, Seifert B, et al. Change of transfusion and treatment paradigm in major trauma patients. Anaesthesia. 2017;72:1317-26.
27. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313:471-82.
28. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care. 2016;20:100.
29. CRASH-2 trial collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377:1096-101.
30. Holcomb JB, del Junco DJ, Fox EE, Wade CE, Cohen MJ, et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg. 2013;148:127-36.